Dr. Narla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Rogel Cancer Center, Rm 3215
Ann Arbor, MI 48109Phone+1 734-615-2411
Summary
- I am physician scientist who specializes in the care of high risk cancer genetics patients. I run a translational cancer research laboratory focused on identifying and characterizing the genetic regulators of cancer development and progression and developing targeted molecular therapies to these alterations.
Education & Training
- Mt Sinai SOM2008 - 2012
- Mount Sinai Hospital2008 - 2011
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2006 - 2008
- Mount Sinai School of MedicinePh.D, Cancer Biology/Genetics, 2001 - 2006
- Icahn School of Medicine at Mount SinaiClass of 2006, MD
- Santa Clara UniversityBS, Biology/Economics, 1993 - 1997
Certifications & Licensure
- MI State Medical License 2018 - 2025
- OH State Medical License 2012 - 2021
- NY State Medical License 2008 - 2013
Awards, Honors, & Recognition
- Harrington Scholarship 2012
- Saul Horowitz, Jr. Memorial Award 2010
- Humanism and Excellence in Teaching, Arnold P. Gold Foundation 2008
- Join now to see all
Publications & Presentations
PubMed
- 48 citationsQuinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung CancerJosephine K Dermawan, Katerina Gurova, John J. Pink, Afshin Dowlati, Sarmishtha De
Molecular Cancer Therapeutics. 2014-09-01 - 129 citationsMutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis.Oonagh Dowling, Analisa DiFeo, Maria Celeste M. Ramirez, Turgut Tukel, Goutham Narla
American Journal of Human Genetics. 2003-10-01 - 61 citationsLoss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I ExpressionBrian Radbill, Ritu Gupta, Maria Celeste M. Ramirez, Analisa DiFeo, John A. Martignetti
Digestive Diseases and Sciences. 2011-02-01
Journal Articles
- Increased alternative splicing of the KLF6 tumor suppressor gene correlates with prognosis and tumor grade in patients with pancreatic cancer.Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL, Eur J Cancer; 44:1895-903
- RAS/PI3-K/AKT promotes cellular growth by enhancing alternative splicing-mediated inactivation of the KLF6 tumor suppressor in human hepatocellular carcinoma.Yea S, Narla G, Zhao X, Villanueva A, Martignetti JA, Llovet JM, Friedman SL, Hepatology ;46:303A-4A
- Drosophila Sin3a mediates cancer-like invasion through multiple pathways.Das TK, Sangodkar J, Negre N, Narla G, and Cagan RL, Cancer Cell
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal DegradationGoutham Narla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Divergent roles of matrix metalloproteinase-2 in hepatic stellate cell activation and liver fibrosis.Radbill B, Gupta R, Alvarez C, Narla G, Martignetti J, Friedman SL, Bansal MB, Hepatology ;40:546A-A
- KLF6 Deficiency Promotes Hepatocellular Carcinoma in Mice and Humans by Increasing Mdm2 Expression and Accelerating P53 Degradation.21. Tarocchi M, Lee UE, Hannivoort R, Loke JC, Narla G, Villanueva A, Llovet JM, Friedman SL, Hepatology ;50:366A-7A
- Join now to see all
Lectures
- Cancer Genetics: Past, Present, and Future.Grand Rounds Seminar, Department of Medicine, Mount Sinai School of Medicine, New York, NY
- The Role of Alternative Splicing in the Regulation of the KLF6 Tumor Suppressor Gene.Fred Hutchinson Cancer Research Center, Seattle, WA
- Personalized Medicine and Lung Cancer Treatment.Charles R. Bronfman Institute for Personalized Medicine, Mount Sinai School of Medicine, New York
- Join now to see all
Press Mentions
- Researchers Zero in on Therapeutic Target for Aggressive Uterine CancerDecember 17th, 2021
- Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive OfficerSeptember 15th, 2021
- Case Western Reserve School of Medicine Awarded $1.6 Million for Undergraduate ResearchNovember 6th, 2018
- Join now to see all
Professional Memberships
- AACRMember
Other Languages
- Spanish, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: